Upload
others
View
6
Download
0
Embed Size (px)
Citation preview
1 Internal Medicine Department, General
Hospital Western Attiki -General Hospital
“Agios Panteleimon”, Nikaia, Pireaus, Greece;
2 1st Department of Internal Medicine,
General Hospital “Agios Panteleimon”-
General Hospital Western Attiki, Nikaia,
Pireaus, Greece;
3 Department of Gastroenterology, National
&Kapodistrian University of Athens, Laiko
General Hospital, Athens, Greece;
4 Biopathology Medicine Department, General
Hospital Western Attiki-General Hospital
“Agios Panteleimon”, Nikaia, Pireaus, Greece;
To emphasize the importance of a
prompt evaluation of recommended
DAA regimens and their vital
contribution to CHC treatment ,
especially to patients with several
comorbidities.
We included CHC pantients who have been treated with the
currently recommended by AASLD DAA regimens and had
completed the treatment the 30th of September.The stage of liver
disease was assessed mainly with transient elastography. Results:80
patients,( 68% of them were males),70% patients had failed to
previous regimen(s) including pegylated interferon
(Peg)+ribavirin.The main source of infection was blood transfusion
and i.v. drug use (60%). Genotype distribution was 11% G1a, 26%
G1b, 3% G2, 45% G3 and 15% G4. 57% were F4 by Metavir score
and 43% F3 .The regimens used were: 3D±R x12wks (n=25),
2D+R x12wks (n=12), SOF+daclatasvir±R x12wks (n=7),
Peg+R+sofosbuvir (SOF) x12wks (n=9), SOF+R x12 (n=10),
SOF+simeprevir±R x12wks (n=10), Harvoni±R x12wks (n=5).
One patient died during treatment due to lung-cancer diagnosis
and one had an episode of hepatic encephalopathy. There were no
additional early treatment discontinuations. Sustained virological
response (SVR) has been achieved in 96% .
The treatment of CHC with 2nd
generation DAAs was excellent
tolerated, had low rates of SAEs or
treatment discontinuation , but there is
always need for more advanced and
specified treatment for persisting CHC
and relapsed patients.